The post Bitcoin Dips Under $63K as Market Enters Full Capitulation Phase appeared on BitcoinEthereumNews.com. Panic selling by short-term holders, combined withThe post Bitcoin Dips Under $63K as Market Enters Full Capitulation Phase appeared on BitcoinEthereumNews.com. Panic selling by short-term holders, combined with

Bitcoin Dips Under $63K as Market Enters Full Capitulation Phase

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Panic selling by short-term holders, combined with the RSI near record lows, suggests that BTC could be transitioning into a full capitulation regime.

Bitcoin (BTC) sellers resumed their activity on Tuesday as the BTC price dropped 4% in 24 hours to an intraday low of $62,700.

Analysts said that Bitcoin has entered an “excess loss-realization” phase, with the relative strength index (RSI) suggesting that a price bottom may be forming. 

Key takeaways:

  • Bitcoin holders continued capitulating, pushing the BTC price below $63,000 on Tuesday. 

  • Bitcoin’s weekly RSI is nearing record lows, signaling a potential bottom.

BTC/USD hourly chart. Source: Cointelegraph/TradingView

Bitcoin holders continue capitulating

The Short-Term Holder SOPR (STH-SOPR), which measures whether short-term holders are selling at a profit or a loss, dropped below 1 after US President Donald Trump announced a new 15% global tariff on Saturday.

Related: Negative Bitcoin funding rate may signal short squeeze above $70K

Currently at 0.95, the metric shows “renewed short-term loss realization,” CryptoQuant analyst XWIN Research Japan said in a Quicktake post on Monday, adding:

Bitcoin: Short-term holder SOPR. Source: CryptoQuant

When analyzing the volume of coins spent at a loss, the seven-day estimated moving average (EMA) of Bitcoin’s short-term holder net realized losses had cooled to $500 million per day, after rising as high as $1.24 billion per day on Feb. 6. 

Glassnode said: 

Bitcoin entity adjusted STH Net realized profit/loss. Source: Glassnode

The 90-day simple moving average (SMA) of Bitcoin’s realized profit/loss ratio has “now fallen below 1, confirming a full transition into an excess loss-realization regime,” Glassnode said.

Bitcoin: Realized profit/loss ratio. Source: Glassnode

Bitcoin’s “most oversold” RSI could be a bottom

Bitcoin’s weekly relative strength index, which measures the speed and change of price movements, reached its “most oversold” score of 25.71 on Tuesday.

These levels were last seen on July 22, a few months before the BTC price bottomed at $15,500 and then embarked on a bull run.

BTC/USD weekly RSI. Source: Cointelegraph/TradingView

In all previous capitulation events when the RSI hit such extreme levels, short-term weakness was common, but a long-term recovery followed every time.

Bitcoin’s weekly RSI is the “most oversold it has ever been, currently at 25.6, which is lower than the previous record low level back after 3AC/Luna crash,” crypto analyst Nic Puckrin said in an X post on Tuesday, adding:

As Cointelegraph reported, Bitcoin’s fear and greed index is at historic lows while the number of bulls predicting new all-time highs is declining, which may be healthy market indicators for a macro bottom. 

This article does not contain investment advice or recommendations. Every investment and trading move involves risk, and readers should conduct their own research when making a decision. While we strive to provide accurate and timely information, Cointelegraph does not guarantee the accuracy, completeness, or reliability of any information in this article. This article may contain forward-looking statements that are subject to risks and uncertainties. Cointelegraph will not be liable for any loss or damage arising from your reliance on this information.

Source: https://cointelegraph.com/news/bitcoin-market-enters-full-capitulation-price-dips-below-63k?utm_source=rss_feed&utm_medium=feed&utm_campaign=rss_partner_inbound

Market Opportunity
Bitcoin Logo
Bitcoin Price(BTC)
$68,029.99
$68,029.99$68,029.99
-0.69%
USD
Bitcoin (BTC) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09